Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases.
Humans
Stomach Neoplasms
/ pathology
Cisplatin
/ therapeutic use
Hyperthermic Intraperitoneal Chemotherapy
/ adverse effects
Peritoneal Neoplasms
/ secondary
Combined Modality Therapy
Retrospective Studies
Hyperthermia, Induced
/ adverse effects
Trastuzumab
/ adverse effects
Cytoreduction Surgical Procedures
/ adverse effects
Survival Rate
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Cytoreductive surgery
Gastric cancer
Hyperthermic intraperitoneal chemotherapy
Peritoneal metastasis
Stomach neoplasms
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
14 May 2023
14 May 2023
Historique:
received:
18
11
2022
revised:
27
02
2023
accepted:
10
04
2023
medline:
7
6
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
ppublish
Résumé
Advanced gastric cancer with synchronous peritoneal metastases (GC-PM) is associated with a poor prognosis. Although cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a promising approach, only a limited number of Western studies exist. To investigate the clinicopathological outcomes of patients who underwent CRS-HIPEC for GC-PM. A retrospective analysis of patients with GC-PM was conducted. All patients were seen at the Department of General and Visceral Surgery, Hospital Barmherzige Brüder, Regensburg, Germany between January 2011 and July 2021 and underwent CRS-HIPEC. Preoperative laboratory results, the use of neoadjuvant trastuzumab, and the details of CRS-HIPEC, including peritoneal carcinomatosis index, completeness of cytoreduction, and surgical procedures were recorded. Disease-specific (DSS), and overall survival (OS) of patients were calculated. A total of 73 patients were included in the study. Patients treated with neoadjuvant trastuzumab ( Based on our experience, CRS-HIPEC is a safe and secure method to improve the survival of advanced GC-PM patients. Prolonged HIPEC duration may serve as a good therapy for these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Advanced gastric cancer with synchronous peritoneal metastases (GC-PM) is associated with a poor prognosis. Although cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is a promising approach, only a limited number of Western studies exist.
AIM
OBJECTIVE
To investigate the clinicopathological outcomes of patients who underwent CRS-HIPEC for GC-PM.
METHODS
METHODS
A retrospective analysis of patients with GC-PM was conducted. All patients were seen at the Department of General and Visceral Surgery, Hospital Barmherzige Brüder, Regensburg, Germany between January 2011 and July 2021 and underwent CRS-HIPEC. Preoperative laboratory results, the use of neoadjuvant trastuzumab, and the details of CRS-HIPEC, including peritoneal carcinomatosis index, completeness of cytoreduction, and surgical procedures were recorded. Disease-specific (DSS), and overall survival (OS) of patients were calculated.
RESULTS
RESULTS
A total of 73 patients were included in the study. Patients treated with neoadjuvant trastuzumab (
CONCLUSION
CONCLUSIONS
Based on our experience, CRS-HIPEC is a safe and secure method to improve the survival of advanced GC-PM patients. Prolonged HIPEC duration may serve as a good therapy for these patients.
Identifiants
pubmed: 37274066
doi: 10.3748/wjg.v29.i18.2850
pmc: PMC10237111
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2850-2863Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All the authors report having no relevant conflicts of interest for this article.
Références
Anticancer Drugs. 2015 Feb;26(2):123-38
pubmed: 25406023
Ann Surg Oncol. 2022 Jan;29(1):152-162
pubmed: 34350529
Acta Pathol Microbiol Scand. 1965;64:31-49
pubmed: 14320675
J Natl Compr Canc Netw. 2022 Feb;20(2):167-192
pubmed: 35130500
BMC Cancer. 2021 Oct 29;21(1):1158
pubmed: 34715810
J Surg Oncol. 2016 Jun;113(7):796-803
pubmed: 27110915
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Eur J Surg Oncol. 2020 Dec;46(12):2292-2310
pubmed: 32873454
Ann Oncol. 2022 Oct;33(10):1005-1020
pubmed: 35914639
Cancers (Basel). 2022 Jul 06;14(14):
pubmed: 35884361
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Pak J Med Sci. 2014 Jan;30(1):145-9
pubmed: 24639849
Gastric Cancer. 2020 Jan;23(1):11-22
pubmed: 31228044
Chirurg. 2021 Jun;92(6):522-527
pubmed: 33620502
Am Surg. 2022 Nov;88(11):2637-2643
pubmed: 35649712
Gastric Cancer. 2021 Jan;24(1):1-21
pubmed: 32060757
Lancet Oncol. 2021 Feb;22(2):256-266
pubmed: 33476595
J Surg Oncol. 2020 Jul;122(1):85-95
pubmed: 32436240
N Engl J Med. 2018 Jan 18;378(3):230-240
pubmed: 29342393
Cancers (Basel). 2019 Jan 11;11(1):
pubmed: 30641919
Anaesthesia. 2022 Nov;77(11):1209-1218
pubmed: 36108174
J Surg Oncol. 2014 Sep;110(3):275-84
pubmed: 25042700
Int J Hyperthermia. 2018 Aug;34(5):532-537
pubmed: 28838265
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Ann Surg Oncol. 2007 Oct;14(10):2702-13
pubmed: 17653801
Curr Oncol. 2022 Mar 02;29(3):1559-1574
pubmed: 35323331
Dig Liver Dis. 2018 Aug;50(8):768-779
pubmed: 29886081
World J Surg Oncol. 2022 Jul 20;20(1):238
pubmed: 35858903
Ann Surg Oncol. 2019 Aug;26(8):2615-2621
pubmed: 31115852
Biomed Res Int. 2017;2017:3083267
pubmed: 28424782
Dis Markers. 2019 Jan 02;2019:7606128
pubmed: 30719182
Anticancer Drugs. 1996 Jul;7(5):548-57
pubmed: 8862723
Eur J Surg Oncol. 2021 Nov;47(11):2757-2767
pubmed: 34001385
Gan. 1968 Jun;59(3):251-8
pubmed: 5726267
Chirurg. 2020 Jan;91(1):37-40
pubmed: 31950198
Ann Oncol. 2015 Jan;26(1):141-148
pubmed: 25316259
Cancer Treat Res. 1996;82:359-74
pubmed: 8849962
J Diabetes Complications. 2017 Sep;31(9):1376-1383
pubmed: 28711195
Xenobiotica. 1996 Apr;26(4):395-403
pubmed: 9173680
Cancer. 1994 Jun 1;73(11):2703-8
pubmed: 8194009
Int J Hyperthermia. 2020;37(1):897-902
pubmed: 32689832
Endoscopy. 2015 Sep;47(9):829-54
pubmed: 26317585
BMC Gastroenterol. 2020 Apr 10;20(1):100
pubmed: 32276616
Ann Surg Oncol. 2021 Jan;28(1):258-264
pubmed: 32556731
Oncol Lett. 2019 Nov;18(5):5205-5214
pubmed: 31612031
Ann Surg Oncol. 2011 Jun;18(6):1575-81
pubmed: 21431408
BMC Cancer. 2017 Dec 28;17(1):893
pubmed: 29282088
Surg Oncol. 2021 Jun;37:101543
pubmed: 33773282
Hepatogastroenterology. 2014 Oct;61(135):2149-55
pubmed: 25713922
World J Gastroenterol. 2014 May 21;20(19):5679-84
pubmed: 24914328
Eur J Surg Oncol. 2019 Sep;45(9):1734-1739
pubmed: 30954352
J Clin Oncol. 2019 Aug 10;37(23):2028-2040
pubmed: 31084544
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686